









































0Leukemia Research 38 (2014) 744–750
Contents lists available at ScienceDirect
Leukemia  Research
j ourna l h om epa ge: www.elsev ier .com/ locate / leukres
ffectiveness  and  safety  of  different  azacitidine  dosage  regimens  in
atients  with  myelodysplastic  syndromes  or  acute  myeloid  leukemia
egina  García-Delgadoa,∗, Dunia  de  Miguelb, Alicia  Bailénc,  José  Ramón  Gonzálezd,
oan  Bargaye, José  F.  Falantes f, Rafael  Andreug, Fernando  Ramosh, Mar  Tormoi,
alut Brunet j, Antonio  Figueredok, Javier  Casan˜o l, Ángeles  Medinam, Llorenc¸ Badiellan,
ntonio  Fernández  Juradoo, Guillermo  Sanzp
Hospital Universitario Virgen de la Victoria, Málaga, Spain
Hospital Universitario de Guadalajara, Madrid, Spain
Hospital Carlos Haya, Málaga, Spain
Hospital Clínico Universitario, Salamanca, Spain
Hospital Son Llatzer, Palma de Mallorca, Spain
Hospital Universitario Virgen del Rocío, IBIS, Seville, Spain
Hospital Doctor Peset, Valencia, Spain
Hospital General de León, León, Spain
Hospital Clínico Universitario de Valencia, Valencia, Spain
Hospital Santa Creu i Sant Pau, Barcelona, Spain
Hospital Virgen Macarena, Seville, Spain
Hospital Reina Soﬁa, Córdoba, Spain
Hospital Costa del Sol, Marbella, Spain
Servei d’Estadística Aplicada, Universitat Autònoma de Barcelona, Barcelona, Spain
Hospital Juan Ramón Jiménez, Huelva, Spain, on behalf of the Asociación Andaluza de Hematología y Hemoterapia, Spain
Hospital Universitario La Fe, Valencia, Spain
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 1 October 2013
eceived in revised form 24 January 2014
ccepted 9 March 2014
vailable online 19 March 2014
a  b  s  t  r  a  c  t
We  investigated  the effectiveness  and  tolerability  of azacitidine  in patients  with  World  Health
Organization-deﬁned  myelodysplastic  syndromes,  or acute  myeloid  leukemia  with  20–30% bone  mar-
row blasts.  Patients  were  treated  with  azacitidine,  with  one  of  three  dosage  regimens:  for 5  days  (AZA 5);
7 days  including  a 2-day  break  (AZA  5-2-2);  or 7  days  (AZA  7);  all 28-day  cycles.  Overall  response  rates
were  39.4%,  67.9%,  and  51.3%,  respectively,  and median  overall  survival  (OS)  durations  were  13.2,  19.1,





better  effectiveness–tolerability  proﬁles  for 7-day  schedules.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).verall survival
afety
. IntroductionMyelodysplastic syndromes (MDS) are a heterogeneous group
f clonal stem cell disorders characterized by ineffective
 This study was  presented in part as two poster presentations: at the 52nd Annual
eeting of the American Society of Hematology, December 4–7, 2010, Orlando, FL,
SA; and at the 17th Congress of the European Hematology Association, June 14–17,
012, Amsterdam, The Netherlands.
∗ Corresponding author. Tel.: +34 951 032 060; fax: +34 951 032 060.
E-mail address: reginagarciadel@yahoo.es (R. García-Delgado).
ttp://dx.doi.org/10.1016/j.leukres.2014.03.004
145-2126/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhematopoiesis leading to gradually worsening cytopenias, and a
high risk of progression to acute myeloid leukemia (AML). Progno-
sis varies widely – patients with International Prognostic Scoring
System (IPSS)-deﬁned Low- or Intermediate (Int)-1-risk MDS  have
a median survival of 5.7 and 3.5 years, respectively. In contrast,
patients with IPSS-deﬁned Int-2- or High-risk MDS  have a shorter
median survival (1.2 and 0.4 years, respectively) and a higher risk
of progression to AML  [1].Azacitidine (Vidaza®; Celgene Corporation, Summit, NJ, USA)
signiﬁcantly reduces red blood cell (RBC)-transfusion dependence,
decreases risk of transformation to AML, improves quality of life,
and increases overall survival (OS) compared with supportive care
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n patients with MDS  across all French–American–British (FAB)
ubtypes [2,3]. In a large phase III trial, azacitidine resulted in sig-
iﬁcantly increased hematologic response rates in higher-risk MDS
atients. It also signiﬁcantly extended OS and time to AML  progres-
ion in higher-risk MDS  patients, and in elderly patients with World
ealth Organization (WHO)-deﬁned AML  with 20–30% bone mar-
ow blasts, when compared with conventional care regimens (best
upportive care, low-dose cytarabine, or intensive chemotherapy)
4–6].
Azacitidine is approved in the USA for the treatment of all
 FAB subtypes of MDS  [7], and is also approved in Europe
or treating adult patients ineligible for hematopoietic stem cell
ransplantation who have IPSS-deﬁned Int-2- or High-risk MDS,
hronic myelomonocytic leukemia with 10–29% bone marrow
lasts without myeloproliferative disorders, or AML with 20–30%
one marrow blasts and multilineage dysplasia according to the
HO criteria [8]. The approved starting dose of azacitidine is
5 mg/m2/day administered subcutaneously (USA and Europe) or
ntravenously (USA only), on days 1–7 of each 28-day cycle for at
east 4–6 cycles (USA) or 6 cycles (Europe), until disease progres-
ion or unacceptable adverse events (AEs) ensue [7,8]. However,
VIDA, a prospective, longitudinal, multicenter patient registry in
he USA, found that the majority of patients receiving azacitidine in
 community-based setting do not receive the approved schedule
f 7 consecutive treatment days [9].
Before receiving marketing authorization in May  2009, azaciti-
ine was available in Spain through clinical trials or compassionate
se. This retrospective, multicenter study analyzed a Spanish
ompassionate use registry to investigate the effectiveness and
olerability of various azacitidine dosing schedules used in daily
linical practice in patients with MDS  or WHO-deﬁned AML  with
0–30% bone marrow blasts.
. Patients and methods
This retrospective analysis of clinical data from a multicenter
panish compassionate use registry included patients who  initiated
zacitidine treatment between February 6, 2006, and May  5, 2009.
he protocol was approved by an independent ethics committee in
pril 2009.
.1. Patients and treatment
Patients aged ≥18 years with either a conﬁrmed diagnosis of
HO-deﬁned MDS, or a conﬁrmed diagnosis of de novo (pri-
ary) or secondary AML  according to WHO  criteria with 20–30%
one marrow blasts were included [10]. All patients were required
o have received ≥1 cycle of azacitidine at a starting dose of
5 mg/m2/day under compassionate use conditions, with a doc-
mented dosage regimen as follows (all 28-day cycles): days 1–5
AZA 5); days 1–5, weekend (2 days) without treatment, followed
y 2 days of treatment (AZA 5-2-2); or days 1–7 (AZA 7). Azaci-
idine dosing schedule and administration route (subcutaneous or
ntravenous) were chosen at the physician’s discretion based on the
atient’s Eastern Cooperative Oncology Group (ECOG) performance
tatus score and the feasibility of weekend drug administration.
.2. Outcome measures
The primary endpoint was clinical response. Hematologic
esponse (deﬁned as complete response [CR], partial response [PR],
arrow CR [mCR], or hematologic improvement [HI]), stable dis-ase (SD), and progressive disease (PD) were assessed according
o the International Working Group 2003 and 2006 criteria for
ML and MDS, respectively [11,12]. Overall response rate (ORR)
as deﬁned as CR + PR + mCR  + HI. Secondary endpoints includedResearch 38 (2014) 744–750 745
OS according to dosing schedule, cytogenetic risk groups at base-
line, best response achieved, and clinical response at four and six
cycles of azacitidine treatment, as well as safety of azacitidine
treatment. OS was deﬁned as time from azacitidine initiation to
death from any cause, and the median duration of follow-up was
1.4 years. Cytogenetics were classiﬁed according to IPSS criteria
[1]. AEs were classiﬁed according to the National Cancer Institute
Common Terminology Criteria for Adverse Events version 3.0.
2.3. Statistical methods
Baseline characteristics between azacitidine dosing groups were
compared using chi-square, Fisher’s exact, or LR chi-square tests for
qualitative variables where appropriate; and analysis of variance,
Mann–Whitney–Wilcoxon, or Kruskal–Wallis tests for quantita-
tive variables as appropriate. Comparison of response to azacitidine
across dosing groups was tested for homogeneity of distributions
using chi-square test.
A multivariate logistic regression identiﬁed potential risk fac-
tors for best overall response. Variables included: bone marrow
blast percentage; platelet count; time since diagnosis; sex; age;
ECOG performance status score; IPSS risk; azacitidine administra-
tion route and dosing schedule; cytogenetics; WHO  classiﬁcation;
disease status; and transfusion dependence. Continuous variables
were: age; time since diagnosis; platelet count; and bone marrow
blast percentage. The categorical variables were: sex; disease sta-
tus; WHO  classiﬁcation; IPSS risk; cytogenetics; ECOG performance
status score; transfusion dependence; azacitidine administration
route; and dosing schedule.
OS was  described with median survival values, 95% conﬁdence
intervals (CIs), as well as using the Kaplan–Meier method. To com-
pare OS between the dosing groups, a Cox proportional hazards
regression model was  used. In a separate multivariate Cox model,
sex, age, disease status, time since diagnosis, WHO  classiﬁca-
tion, IPSS risk, cytogenetics, ECOG performance status score, and
azacitidine administration route and dosing schedule were
included as prognostic factors for OS. To simplify the multivariate
model, a backward selection method was  applied, using p ≥ 0.05 as
a criterion for variable exclusion.
The relationship between response to azacitidine and OS was
analyzed using a Cox proportional hazards model. To prospec-
tively explore this relationship, responses to azacitidine treatment
at cycles 4 and 6 were used as dependent variables to explain and
predict the OS of those patients alive and not censored after 4 or 6
months of treatment, respectively.
Statistical analyses were performed by the statistics department
of the Autonomous University of Barcelona, Spain, using SAS® soft-
ware version 9.2 (SAS Institute Inc., Cary, NC, USA). The nominal
signiﬁcance level was  5% (p < 0.05) for all statistical tests performed.
No corrections for multiplicity of statistical tests were applied due
to the exploratory nature of the study. Data were included up to a
cutoff date of June 30, 2010.
3. Results
3.1. Patient demographics
Of 240 patients treated with azacitidine-based regimens in the
Spanish compassionate use registry, 200 met  the inclusion crite-
ria: 66 (33.0%) received AZA 5; 56 (28.0%) received AZA 5-2-2; and
78 (39.0%) received AZA 7. Baseline characteristics were sim-
ilar across the 3 dosing groups (Table 1). The majority of
patients (67.0%) were male and 83.0% had primary MDS.
The median age was  69 years (range 28–86 years). There
were fewer patients without excess blasts in the AZA 5 and
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Table  1
Patient baseline characteristics and details of azacitidine administration according to azacitidine dosing schedule.
Characteristic Azacitidine dosing schedulea Total (n = 200) p-Value
AZA 5 (n = 66) AZA 5-2-2 (n = 56) AZA 7 (n = 78)
Median age, years (range)b 70 (28–86) 69 (29–82) 70 (33–82) 69 (28–86) 0.6685
Male,  n (%) 46 (69.7) 36 (64.3) 52 (66.7) 134 (67.0) 0.5863
Disease status, n (%) 0.3694
Primary MDS 55 (83.3) 50 (89.3) 61 (78.2) 166 (83.0)
Secondary MDS  5 (7.6) 2 (3.6) 8 (10.3) 15 (7.5)
Primary/secondary MDS  unknown 1 (1.5) 0 0 1 (0.5)
AML  1 (1.5) 2 (3.6) 6 (7.7) 9 (4.5)
Refractory AML  4 (6.1) 2 (3.6) 3 (3.8) 9 (4.5)
Median time from diagnosis to AZA therapy, months (range)c 7.4 (0–174.0) 7.5 (0–83.4) 6.6 (0–202.0) 7.4 (0–202.0) 0.8423
WHO  classiﬁcation, n (%)d 0.0883
RA  3 (4.9) 2 (3.8) 5 (7.2) 10 (5.5)
RCMD 10 (16.4) 14 (26.9) 17 (24.6) 41 (22.5)
RARS  5 (8.2) 2 (3.8) 12 (17.4) 19 (10.4)
RCMD-RS 3 (4.9) 0 2 (2.9) 5 (2.7)
RAEB-1 19 (31.1) 10 (19.2) 11 (15.9) 40 (22.0)
RAEB-2 11 (18.0) 14 (26.9) 13 (18.8) 38 (20.9)
MDS-U 3 (4.9) 3 (5.8) 6 (8.7) 12 (6.6)
MDS  del(5q) 1 (1.6) 3 (5.8) 0 4 (2.2)
Unknown 6 (9.8) 4 (7.7) 3 (4.3) 13 (7.1)
IPSS  risk group, n (%)e 0.8443
Low  13 (19.7) 10 (17.9) 16 (20.5) 39 (19.5)
Int-1  28 (42.4) 23 (41.1) 27 (34.6) 78 (39.0)
Int-2  15 (22.7) 12 (21.4) 15 (19.2) 42 (21.0)
High 3 (4.5) 6 (10.7) 10 (12.8) 19 (9.5)
Unknown 7 (10.6) 5 (8.9) 10 (12.8) 22 (11.0)
Cytogenetic risk, n (%) 0.7241
Poor 7 (10.6) 5 (8.9) 8 (10.3) 20 (10.0)
Intermediate 45 (68.2) 37 (66.1) 41 (52.6) 123 (61.5)
Good  1 (1.5) 1 (1.8) 2 (2.6) 4 (2.0)
Unknownf 13 (19.7) 13 (23.2) 27 (34.6) 53 (26.5)
ECOG status by grade, n (%) 0.1767
0 17 (25.8) 8 (14.3) 14 (17.9) 39 (19.5)
1  27 (40.9) 36 (64.3) 32 (41.0) 95 (47.5)
2  12 (18.2) 5 (8.9) 18 (23.1) 35 (17.5)
3  3 (4.5) 3 (5.4) 5 (6.4) 11 (5.5)
Unknown 7 (10.6) 4 (7.1) 9 (11.5) 20 (10.0)
Median number of AZA cyclesg (range) 6 (1–26) 8 (1–29) 8 (1–34) 8 (1–34) 0.8677
Subcutaneous AZA administration, n (%) 52 (78.8) 51 (91.1) 66 (84.6) 169 (84.5) 0.1745
AML, acute myeloid leukemia; AZA, azacitidine; ECOG, Eastern Cooperative Oncology Group; Int, Intermediate; IPSS, International Prognostic Scoring System; MDS, myelodys-
plastic  syndromes; MDS-U, MDS  unclassiﬁed; RA, refractory anemia; RAEB, RA with excess blasts; RARS, RA with ringed sideroblasts; RCMD, refractory cytopenia with
multilineage dysplasia; RCMD-RS, RCMD with ringed sideroblasts; WHO, World Health Organization.
a Patients were not pretreated.
b Data were available for 63 patients in the AZA 5 group, 51 patients in the AZA 5-2-2 group, and 77 patients in the AZA 7 group.
c Data were available for 61 patients in the AZA 5 group, 47 patients in the AZA 5-2-2 group, and 73 patients in the AZA 7 group.
d Comprises only those 182 patients with MDS  according to WHO  classiﬁcation (primary and secondary MDS), including 61 patients in the AZA 5 group, 52 patients in the

















Ae At start of treatment.
f Due to insufﬁcient bone marrow sample.
g Data were available for 66 patients in the AZA 5 group, 55 patients in the AZA 5
ZA 5-2-2 groups (p = 0.09). Most MDS  patients had IPSS-
eﬁned Low- or Int-1-risk disease; 62.1%, 59.0%, and 55.1% in
he AZA 5, AZA 5-2-2, and AZA 7 groups, respectively. The
edian time from diagnosis in the overall population was
.4 months (95% CI 16.1–26.4 months). Patients in the AZA 5-2-
 and AZA 7 groups received a median of 8 cycles of azacitidine,
hereas patients in the AZA 5 group received a median of 6 cycles.
zacitidine was administered subcutaneously in 78.8%, 91.1%, and
4.6% of patients in the AZA 5, AZA 5-2-2, and AZA 7 groups, respec-
ively. Only 18 patients with AML  and 20–30% blasts were included
n the study: 5 patients (28%) received AZA 5, 4 patients (22%)
eceived AZA 5-2-2, and 9 patients (50%) received AZA 7.
.2. Clinical responseOf the 199 patients for whom data were available, 104 (52%)
chieved any response (CR, PR, mCR, or HI). The ORRs varied across
he 3 groups: 39.4% for AZA 5; 67.9% for AZA 5-2-2; and 51.3% for
ZA 7 (overall, p = 0.0094; AZA 5 vs. AZA 5-2-2, p = 0.0021; AZA 5 vs.roup, and 78 patients in the AZA 7 group.
AZA 7, p = 0.1530; AZA 5-2-2 vs. AZA 7, p = 0.0489) (Table 2). In the
Cox multivariate model, increased platelet count (p = 0.0247) and
azacitidine dose (AZA 5-2-2 vs. AZA 5; p = 0.0365) were predictive
of response.
Among patients with available time-to-response data in the
AZA 5 (n = 36), AZA 5-2-2 (n = 37), and AZA 7 (n = 46) groups, best
response was  achieved after a median of 4 azacitidine cycles (range
1–22 cycles).
3.3. Overall survival
The median duration of follow-up was 1.4 years (range 0.1–3.4
years). Median OS duration in the overall study population was
16.5 months (95% CI 12.4–19.1 months).
Reported 1-year OS rates were 52.2%, 69.0%, and 57.6% for the
AZA 5, AZA 5-2-2, and AZA 7 groups, respectively (p = 0.2952). The
respective median OS durations were 13.2 months (95% CI 9.3–17.5
months), 19.1 months (95% CI 13.1–26.0 months), and 14.9 months
(95% CI 9.6–21.4 months) (p = 0.3305) (Fig. 1). Median OS according
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Table  2
Clinical response rates according to azacitidine dosing schedule.
Characteristic, n (%) Azacitidine dosing schedule Total (n = 200)
AZA 5 (n = 66) AZA 5-2-2 (n = 56) AZA 7 (n = 78)
CR 8 (12.1) 11 (19.6) 13 (16.7) 32 (16.0)
mCR  7 (10.6) 13 (23.2) 8 (10.3) 28 (14.0)
PR  6 (9.1) 6 (10.7) 13 (16.7) 25 (12.5)
HI  5 (7.6) 8 (14.3) 6 (7.7) 19 (9.5)
SD  18 (27.3) 7 (12.5) 11 (14.1) 36 (18.0)
PD  22 (33.3) 10 (17.9) 27 (34.6) 59 (29.5)
Missing 0 1 (1.8) 0 1 (0.5)
ORR  (CR + mCR  + PR + HI), % 39.4 67.9 51.3 52.0
AZA, azacitidine; CR, complete response; HI, hematologic improvement; mCR, marrow CR; ORR, overall response rate; PD, progressive disease; PR, partial response; SD,  stable
disease.
+ Censored































































Aig. 1. Overall survival according to azacitidine dosing schedule received (n = 200). 
he  study.
o IPSS was 24.4 months for Low-risk, 16.5 months for Int-1-risk,
4.9 months for Int-2-risk, and 10.4 months for High-risk patients.
he characteristics of patients with Low- and Int-1-risk MDS  were
urther analyzed according to the scoring system described by
arcia-Manero et al. [13] (Table 3). OS was similar across cytoge-
etic risk groups (p = 0.4852).
In the Cox multivariate model there were no variables or inter-
ctions with predictive value (data not shown).
Median OS duration in the overall study population was  signiﬁ-
antly longer in patients who achieved any response (CR, PR, mCR,
r HI) compared with non-responders (SD and PD) (23.3 months
95% CI 19.4–36.1 months] vs. 7.4 months [95% CI 5.2–10.5 months],
espectively; p < 0.0001). Median OS according to best ORR was
6.0 months for CR (95% CI 22.5—not reached [NR]), 23.3 months
or PR (95% CI 14.8—NR), 21.4 months for mCR  (95% CI 9.8–21.4
onths), 19.7 months for HI (95% CI 13.2–42.2 months), 10.7
onths for SD (95% CI 6.5–17.4 months), and 4.5 months for PD
95% CI 3.1–6.2 months). There were differences in OS according to
able 3
ssigned scores in lower-risk patients based on the prognostic score described by Garcia-
Score Frequency Percentage 
0 1 0.85 
1  2 1.71 
2  11 9.40 
3  17 14.53 
4  32 27.35 
5  39 33.33 
6  14 11.97 
7  1 0.85 The 3 azacitidine dosing groups were not balanced at baseline due to the nature of
best response achieved at azacitidine cycles 4 and 6 (all p < 0.0001;
Fig. 2).
Overall, SD or achievement of any response (CR, PR, mCR, or
HI) to azacitidine was associated with signiﬁcantly reduced risk of
death relative to PD (all p ≤ 0.001). OS was signiﬁcantly improved
in patients with CR or PR at azacitidine cycles 4 and 6 compared
with patients with SD as the best response (all p < 0.05). In addi-
tion, patients with HI at cycle 6 (with no other response achieved
previously) had signiﬁcantly better OS compared with those with
SD (p = 0.0118).
3.4. Safety
The most common grade 3 and 4 hematologic AE in the AZA
5 (n = 66), AZA 5-2-2 (n = 56), and AZA 7 (n = 78) groups was neu-
tropenia in 39.4%, 19.6%, and 24.4% of patients, respectively. The
rates of grade 3 and 4 thrombocytopenia were 15.2%, 8.9%, and
10.3%, respectively, and rates of grade 3 and 4 anemia were 10.6%,
Manero et al. [13] (n = 117).





























Patients at risk,  n
9 9mCR  4 1 0
18 18SD 11 4 0
21 21PD 7 4 1 0
21 21PR 16 10 4 0
16 16HI 13 5 3 2 2
53 53CR 35 18 8 4 1
p = 0.0001 
Patients at risk,  n
+ Censored
4mCR  1 0
27PD 16 5 3 1 0
19PR 18 16 9 4 1 0
46SD 38 23 8 2 1 1
28HI 26 18 10 3 1 1
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aig. 2. Overall survival according to best response to azacitidine therapy after cyc
n  = 162) and 6 months (n = 138) of azacitidine treatment, respectively.
.2%, and 10.2%, respectively. Grade 5 neutropenia occurred in 9.1%,
5.0%, and 7.7% of patients in the AZA 5, AZA 5-2-2, and AZA 7
roups, respectively. Grade 5 thrombocytopenia occurred in 21.2%,
9.6%, and 16.7% of patients; and grade 5 anemia occurred in 22.7%,
4.3, and 15.4% of patients in the 3 dosing groups. Details on other
ematologic and non-hematologic AEs were incompletely reported
nd, therefore, not statistically analyzed. Dose modiﬁcations due to
Es were required in 13.6% of patients in the AZA 5 group, 28.6%
n the AZA 5-2-2 group, and 14.1% in the AZA 7 group. Treatment
nterruptions were reported in 15.2%, 8.9%, and 15.4% of patients in
he 3 dosing groups.
. Discussion
Data obtained from retrospective analysis of compassionate use
egistries should be cautiously analyzed in order to avoid as much
s possible any bias in the observation, analysis, or interpretation of
he results. This retrospective analysis of clinical data from a multi-
enter Spanish azacitidine compassionate use registry shows that
zacitidine was effective and generally well tolerated in patients) and cycle 6 (B) in those patients who were alive and not censored at 4 months
with MDS  or WHO-deﬁned AML  with 20–30% bone marrow blasts
treated in a community-based practice setting.
The approved azacitidine dosing schedule is 75 mg/m2/day on
days 1–7 of each 28-day treatment cycle (AZA 7). However, it has
been shown that the majority of patients treated in community-
based hematology clinics do not receive the approved schedule
of treatment [9]. Most patients with lower-risk MDS  receive <7
days of azacitidine (consecutive or non-consecutive) treatment,
whereas most patients with higher-risk MDS  receive ≥7 days of
azacitidine (consecutive or non-consecutive) treatment per 28-day
cycle. A prospective, community-based phase II study compared
the efﬁcacy and safety of alternative azacitidine schedules with-
out weekend dosing: AZA 5, AZA 5-2-2, and azacitidine for 5
days followed by a 2-day weekend break and then an additional
5 days of treatment (AZA 5-2-5) in a predominantly lower-risk
MDS  patient population [14]. The rates of HI and RBC-transfusion
independence together with safety evaluations reported appeared
consistent with those seen using the approved dosing regimen;
however, a direct comparison of the alternative azacitidine dos-
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In the present study, which included 58.5% of patients with IPSS
ow- or Int-1-risk MDS, the 3 dosing schedules were distributed
pproximately equally across the total study population. ORRs
CR + PR + mCR  + HI) appeared higher with the AZA 5-2-2 dosing
chedule (67.9%) compared with AZA 7 (51.3%) and AZA 5 (39.4%).
he ORR for the entire patient cohort was 52.0%. In a prospective,
hase III study in 179 patients with higher-risk MDS  or AML  with
0–30% bone marrow blasts treated with azacitidine, the rates of
verall response (deﬁned as CR + PR) and HI were 29% and 49%,
espectively [4]. Retrospective analyses in patients with lower-risk
DS  or AML  with 21–38% bone marrow blasts treated with azac-
tidine reported ORRs of 45.6% (deﬁned as CR + PR + mCR  + HI) and
0% (deﬁned as CR + PR + HI), respectively [15,16].
OS is an important treatment goal, particularly in patients with
igher-risk MDS  or AML. A prospective, phase III study reported sig-
iﬁcantly higher median OS with azacitidine versus conventional
are regimens in patients with higher-risk MDS  (24.5 months [95%
I 9.9—NR] vs. 15.0 months [95% CI 5.6–24.1]); and in elderly AML
atients with 20–30% bone marrow blasts (24.5 months [95% CI
4.6—NR] vs. 16.0 months [95% CI 11.5–17.5]) [4,6]. In the current
tudy, median OS was 13.2, 19.1, and 14.9 months in the AZA 5,
ZA 5-2-2, and AZA 7 groups, respectively. A retrospective analysis
f 74 patients with lower-risk MDS  treated with azacitidine in an
talian named patient program showed that 71% remained alive at
 median follow-up of 15 months [15].
As the OS of lower-risk patients was lower than expected [1],
hese patients were analyzed using the recently deﬁned prognostic
ool for lower-risk patients, which includes variables such as age,
emoglobin levels, platelets, cytogenetics, and bone marrow blast
ount [13]. A majority of lower-risk patients were classiﬁed with
levated scores and estimated median survival times of between
4 and 22 months. It is possible that their worse prognosis deter-
ined their treatment with azacitidine within the compassionate
se program.
In the present heterogeneous study population, OS differed
cross azacitidine dosing groups but the differences observed were
ot statistically signiﬁcant, most likely as a result of the small
atient numbers in each dosing group; these results need to be con-
rmed in a prospective randomized study. Interestingly, the quality
f response to treatment had a signiﬁcant impact on OS in the over-
ll patient cohort. Furthermore, in line with a previous prospective
tudy [17,18], this survival advantage was not necessarily depend-
nt on achieving CR and PR; however, best response achieved with
zacitidine at cycles 4 and 6 was predictive for OS.
The median number of azacitidine cycles received was 6, 8, and
 in the AZA 5, AZA 5-2-2, and AZA 7 groups, respectively. This
ould help explain the lower response rates observed in the AZA 5
roup, as additional cycles of azacitidine therapy have been shown
o improve the quality of response in patients with higher-risk
DS  [19]. Also, a median of 9 cycles of azacitidine was previously
emonstrated to be associated with prolonged OS versus conven-
ional care [4].
The most common hematologic AEs reported with azacitidine
ere neutropenia, thrombocytopenia, and anemia, whereas non-
ematologic events include injection site reactions, fatigue, and
astrointestinal events, such as nausea and vomiting [2,4,14,15,20].
n line with these studies, the most common grade 3 and 4 hema-
ologic AEs reported here were neutropenia, thrombocytopenia,
nd anemia with rates of 20–39%, 9–15%, and 7–11%, respectively.
he dosing group with the most hematologic toxicities experienced
he fewest dose modiﬁcations, possibly because the treatment was
topped.The data presented here are based on a retrospective analy-
is and are thereby subject to any limitations normally imposed
n such analyses, such as potential selection bias resulting from
d hoc assessment of the data set. Among evaluable patients, dataResearch 38 (2014) 744–750 749
were often incomplete for individual patients. Furthermore, there
was a lack of stratiﬁcation across the 3 dosing groups. This study
included patients across all IPSS subgroups; therefore, the authors
caution the application of these results to speciﬁc IPSS subgroups
of MDS. The limited sample size may  have prevented demonstra-
tion of statistical differences across the azacitidine dosing groups.
Despite these limitations, the study reports daily clinical practice
data in a wide range of patients, providing valuable information
on the effectiveness and safety proﬁle of various azacitidine dosing
schedules.
In conclusion, these retrospective ﬁndings in mainly lower-risk
MDS and WHO-deﬁned AML  patients with 20–30% bone mar-
row blasts, registered in a community-based Spanish azacitidine
compassionate use registry, show differences in overall clinical
response and OS across 3 different azacitidine dosing schedules
used in daily clinical practice. The effectiveness–tolerability proﬁle
appears to be superior for the 7-day azacitidine schedules (AZA 5-
2-2 and AZA 7) compared with the 5-day schedule (AZA 5). Quality
of response achieved during azacitidine treatment was associated
with prolonged survival.
Role of the funding source
The MDS  Group of the Asociación Andaluza de Hematología
y Hemoterapia received an unrestricted educational grant from
Celgene Corporation. The study sponsors had no role in study
design, collection, analysis and interpretation of data; writing of
the manuscript; or the decision to submit the manuscript for pub-
lication.
Conﬂict of interest statement
RGD and JB have received research funding from Celgene Cor-
poration. D de M has participated in speakers bureaus for Celgene
Corporation. FR has been a consultant, a member of an entity’s
board of directors or advisory committee (s), participated in speak-
ers bureaus, and received research funding and honoraria from
Celgene Corporation. GS has participated in advisory committees
and received honoraria from Celgene Corporation, Amgen, and
Novartis; and participated in an advisory committee for Boehringer
Ingelheim Pharma GmbH. All other authors have no conﬂict of
interest to disclose.
Contributors
RGD developed the concept and design of the study, and col-
lected data; D de M,  AB, JRG, JB, JFF, RA, FR, MT,  SB, AF, JC, AM,
AFJ, and GS collected data; LB analyzed the data; and all authors
provided ﬁnal approval of the version to be submitted.
Acknowledgments
The authors received editorial/writing support provided by
Christian Geest, PhD, from Excerpta Medica, funded by Celgene
Corporation. The authors had full access to the data and are fully
responsible for content and editorial decisions for this manuscript.
Appendix A.
The following Spain-based hematologists also contributed to
this study manuscript by providing their patients’ data: Rafael F.
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